
Hong Kong’s Department of Health convened the inaugural meeting of its Medical Device Advisory Panel on 19 November 2026, according to a Hong Kong Government press release. The panel, chaired by Professor Philip Chiu, will advise on the proposed statutory regulatory regime for medical devices, which would replace a voluntary listing system that has run since 2004. For device developers, universities and research offices in Hong Kong, it is the clearest sign yet of how legislation is being prepared.
What happened
The Medical Device Advisory Panel under the Department of Health held its first meeting on 19 November 2026, the Government said in a press release issued the same day. Professor Philip Chiu chairs the panel, whose members come from the medical, engineering, and innovation and technology sectors. The full membership list is published on the Department of Health’s Medical Device Division website.
At the meeting the Department of Health presented the Medical Device Administrative Control System (MDACS), which has operated on a voluntary basis for more than 20 years, together with the Government’s legislative proposal for a new statutory regime. According to the release, the panel supported taking the legislation forward.
Key details: six principles and the panel’s job
The release says the proposal rests on six principles:
- public safety;
- innovation;
- alignment with international practice;
- building on local experience;
- controlling devices at source through licensing of upstream traders; and
- risk-based, tiered registration of devices.
The panel’s stated role is to gather stakeholder feedback during the legislative process and to advise on how MDACS operates and on transitional arrangements. The Government’s stated goals are to strengthen regulation of the safety, quality and performance of medical devices, protect public health, support orderly industry development, and position Hong Kong as an international hub for health and medical innovation. The release links the work to the 2026-2030 Five-Year Plan and the 2026 Policy Address, both of which call for stronger drug and device regulation and for a Centre for Medical Products Regulation (CMPR).
The release does not name a bill or ordinance; it refers to a new statutory regime the Government is preparing.
Background: from voluntary listing to a statutory regime
Hong Kong has no dedicated medical device law. In a written reply to the Legislative Council on 28 January 2026, Secretary for Health Professor Lo Chung-mau said some products fall under general laws such as the Pharmacy and Poisons Ordinance, the Consumer Goods Safety Ordinance and the Trade Descriptions Ordinance, depending on the product. The Department of Health introduced MDACS in 2004; it is not statutory, and more than 8,900 devices had been listed under it by January 2026. The reply also said the Government plans to submit a legislative proposal on device regulation to the Legislative Council in 2026, and that the 2025 Policy Address announced a CMPR to be set up in 2026 consolidating regulation of Western medicines, Chinese medicines and medical devices, with a Medical Products Regulation Bill to follow.
The institutional groundwork goes back further. The Department of Health announced a Preparatory Office for the CMPR on 5 June 2024. The Government then described a “primary evaluation” approach to medical products, delivered in six major steps, with the aim of making Hong Kong an internationally recognised regulatory authority. It said it wanted to attract local and overseas drug and device companies to carry out research and development and clinical trials in Hong Kong, and to win international and Mainland recognition for its approval mechanism.
Law firm CMS, in a legal update of 11 July 2025, summarised what mandatory regulation would change. Today, no comprehensive pre-market mechanism assesses the safety, performance and quality of every device, and unlisted devices are governed by general laws not designed for them. Once legislation passes, CMS wrote, all medical devices supplied in Hong Kong would have to be registered unless exempted; regulated devices would need to meet the internationally recognised Essential Principles of Safety and Performance; labelling, packaging and marketing rules would tighten; and a dedicated adverse event reporting system would cover all devices, where the current system covers only MDACS-listed products.
Reaction and the legislative timetable
The Standard reported on 9 April 2026 that the CMPR will be set up under the Department of Health, that drug regulatory powers for Chinese and Western medicines will move to the Director of Health, that the separate ordinances for the two will be revised, and that the Government plans to present the bill to the Legislative Council in the second half of 2026. The paper quoted Health Bureau documents describing the aim of streamlining the framework and aligning it with international standards, and of supporting international cooperation on pharmaceutical and device regulation.
What it means for researchers, universities and research offices
The panel meeting does not change any rule today: MDACS listing remains voluntary until the Legislative Council passes a law. The practical consequences are still worth planning for.
Academic device developers. A university group that turns a prototype into a product supplied in Hong Kong would, under the proposal as CMS summarised it, need registration unless the product is exempt, and its risk tier would drive the evidence required. Technology transfer and spin-out teams should map which of their devices would fall into a regulated class, using general definitions such as those in what is a medical device, and follow how exemptions are drawn in the bill.
Clinical investigations. The Secretary for Health’s January reply stated that innovative devices must undergo scientific validation, including clinical trials, to show safety and efficacy. Investigators and sponsors designing device studies can already align protocols with international good clinical practice, for example ISO 14155, and review the design questions covered in medical device clinical trials. Because the Government says it wants to align with international practice and draw clinical-trial activity to Hong Kong, evidence generated to recognised standards is the most portable choice.
Research offices and quality teams. Offices that support device work should expect questions about transitional arrangements, which the panel will advise on, and about documentation: quality management, labelling, post-market monitoring and adverse event reporting. Standards-based practice, outlined in ISO standards for medical devices, is the common ground between the Essential Principles approach and what funders and ethics committees already ask for.
Institutions working with the Mainland. The Government’s stated aim of Mainland recognition for Hong Kong’s approval mechanism means cross-boundary projects should track how the CMPR’s primary evaluation approach develops.
What happens next
The panel will collect stakeholder views as the legislation progresses and advise on MDACS operation and the transition. The Government has said it intends to put its legislative proposal to the Legislative Council in 2026, and the CMPR is due to be set up in 2026. Research offices can follow the Department of Health’s Medical Device Division website and Legislative Council papers for the bill and the transitional arrangements.
Sources
- Hong Kong Government, “DH’s Medical Device Advisory Panel holds inaugural meeting”, press release, 19 November 2026
- Hong Kong Government, Legislative Council written reply (LCQ16) by the Secretary for Health, 28 January 2026
- news.gov.hk, “Medical products body established”, 5 June 2024
- CMS, “Hong Kong Centre for Medical Products Regulation to be established by the end of 2026”, 11 July 2025
- The Standard, “HK to launch Centre for Medical Products Regulation”, 9 April 2026







